CNS & Neurological Disorders - Drug Targets

(Formerly Current Drug Targets - CNS & Neurological Disorders)

Stephen D. Skaper  
Department of Pharmaceutical and Pharmacological Sciences
University of Padova
Padova
Italy

Back

Wnt/β-Catenin Signaling in Alzheimer's Disease

Author(s): Giancarlo V. De Ferrari, Miguel E. Avila, Matias A. Medina, Eduardo Perez-Palma, Bernabe I. Bustos and Marcelo A. Alarcon

Affiliation: Center for Biomedical Research and FONDAP Center for Genome Regulation, Universidad Andres Bello, Republica #239, PO Box 8370134, Santiago, Chile.

Keywords: Alzheimer's disease, amyloid precursor protein, tau, apolipoprotein E, Wnt/β-catenin signaling, lithium.

Abstract:

Alzheimer’s disease is a neurodegenerative disorder that causes a progressive decline of mental and cognitive processes such as memory, judgment and reasoning. We proposed earlier that a sustained loss of function of Wnt/β- catenin signaling components underlies the onset and progression of the disease. Here, we discuss recent data on the involvement of Wnt/b-catenin signaling on amyloid precursor protein (APP) processing, Aβ peptide neurotoxicity, τ phosphorylation, and modulation of Apolipoprotein E function in the brain. We conclude that several components of the cascade are actively engaged in the events leading to AD neuropathology and propose that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients. In summary, data accumulated during the past decade confirm some important predictions of our hypothesis where components of this signaling cascade are actively engaged in the events leading to AD neuropathology and that compounds that mimic activation of this signaling cascade, such as lithium, should be considered for therapeutic intervention in Alzheimer's patients.

Reprint ePrint Rights & PermissionsPrintExport

Article Details

VOLUME: 13
ISSUE: 5
Page: [745 - 754]
Pages: 10
DOI: 10.2174/1871527312666131223113900